Inhaled antibiotic for Mycobacterium xenopi lung infection
Part of Infections, Lungs & breathing clinical trials.
This trial tests an inhaled antibiotic (amikacin liposome) for people with a lung infection caused by a germ called Mycobacterium xenopi. The goal is to see if this treatment can help fight the infection with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a lung infection caused by a specific germ called Mycobacterium xenopi.
- You cannot be pregnant or breastfeeding, and if you could become pregnant, you must use reliable birth control.
- You cannot have severe kidney failure or take certain medications that interact with the study drugs.
- You must not be allergic to any of the study drugs or their ingredients (like soy or certain antibiotics).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares two antibiotics—clarithromycin and azithromycin—to treat lung infection caused by Mycobacterium avium complex (MAC). It may help by showing which antibiotic works better and is safer for people who need MAC treatment.
This trial tests whether adding an inhaled antibiotic (amikacin) to standard IV antibiotics can better treat a serious lung infection (pneumonia caused by Gram-negative bacteria) in patients on a heart-lung machine (ECMO) and a breathing tube. If you or your loved one is on ECMO and has this type of pneumonia, this study may offer a new treatment approach.
This trial tests whether a shorter course of antibiotics works for people with a specific type of lung infection caused by Mycobacterium avium complex (MAC). It aims to find a treatment that is just as effective but easier to complete.
This trial tests a new combination of antibiotics (Arm D) against the standard treatment for people with a difficult-to-treat lung infection called Mycobacterium abscessus. It is for adults and teens aged 12 and older, including those with cystic fibrosis.
This trial studies how much medicine is needed (based on lab results) to treat MAC lung disease, an infection in the lungs. If you already have MAC and are receiving the recommended core antibiotics, your care may help researchers link treatment details to lab measurements.
This trial tests whether inhaled hypertonic saline can improve symptoms and lung health in people with a specific lung infection called MAC. It targets adults with confirmed MAC infection and bronchiectasis who are not already on certain MAC medications.
Hear when a new Lung Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.